iCamumo
iCamumo is a Suzhou-based clinical-stage biotech founded in 2021 that develops off-the-shelf, iPSC-derived cell therapy pharmaceuticals for oncology and chronic degenerative diseases using its proprietary TNT reprogramming platform, with pipeline candidates in IIT and preclinical stages and global rights across all assets.
- Company typePrivate
- Founded2021
- HeadquartersSuzhou, China
- Headcount51–100
- GTM typeB2B
- OfferingHardware or Manufacturing
What iCamumo does
iCamumo (艾凯利元生物科技有限公司 / iCamuno Biotherapeutics) is a private, clinical-stage Chinese biotechnology company founded in March 2021 and headquartered in Suzhou, with additional research operations in Hangzhou and Melbourne. The company develops off-the-shelf, universal cell therapy pharmaceuticals derived from induced pluripotent stem cells (iPSCs), targeting oncology (solid tumors, B-cell malignancies, multiple myeloma) and chronic degenerative diseases (Parkinson's disease, osteoarthritis, ophthalmology, ALS disease models).
The company's scientific foundation is its proprietary TNT (Transient Naive Treatment) reprogramming technology, developed by founder Liu Xiaodong and published in Nature, which eliminates epigenetic memory and aberrations from iPSCs to produce 'super iPSCs' (iCam-iPSC) that are molecularly and functionally closer to embryonic stem cells. This sits inside three integrated platforms — iCam-iPSC Super Stem Cell, iCam-Intelligent Engineering (gene editing), and iCam-Algorithm-Guided Expansion and Differentiation (AI plus single-cell multi-omics) — anchored by a GMP-grade three-tier iPSC cell bank. The disclosed pipeline comprises seven candidates (ICA01, ICA01TB, ICA2001, ICA3001 in oncology; ICA03, ICA06, ICA07 in regenerative indications), with ICA01 in investigator-initiated clinical trials for solid tumors and ICA03 in clinical preparation in Australia.
iCamumo operates a platform-plus-product business model with no commercial revenue to date. Revenue is expected to derive from off-the-shelf cell therapy product sales upon regulatory approval and from licensing/royalty arrangements for its TNT and differentiation technologies. The company has raised over USD 55M cumulatively from investors including Westlake Innovation Investment, 5Y Capital, Lianxin Capital, Kaywind Ventures, InnoVision Capital, Deren Capital, ByteDance, and Kingson Pharma, with a RMB 100M+ A++ round closed in August 2023. Go-to-market relies on IIT-style clinical collaborations with leading hospitals (Zhejiang University Second Affiliated Hospital), international research partnerships (University of Western Australia, Monash University, University of Adelaide), and patient-platform alliances (Cai Lei / Jianyu Huzhu Zhijia for ALS), with all pipeline products carrying global rights.
iCamumo firmographics
Firmographics- Name
- iCamumo
- Legal name
- 艾凯利元生物科技有限公司
- Website
- https://icamunobio.com
- Company type
- Private
- Founded year
- 2021
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- iCamumo is a Suzhou-based clinical-stage biotech founded in 2021 that develops off-the-shelf, iPSC-derived cell therapy pharmaceuticals for oncology and chronic degenerative diseases using its proprietary TNT reprogramming platform, with pipeline candidates in IIT and preclinical stages and global rights across all assets.
- Ownership category
- akta.pro rank
iCamumo industry classification
Industry- Product category
- Cell Therapy Biopharmaceuticals
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Pharmaceutical and Medicine Manufacturing (3254)
- SIC
- Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Stem Cell Therapies (MSC/iPSC/HSC-derived) (HLAAABAE)
- akta.pro secondary industries
- Stem Cell–Based Regenerative Therapies (HLAAAGAA), Cell Therapy Developers (Allogeneic/Off-the-shelf) (HLAAABAB), Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods) (HLAAABAL)
Keywords
Where iCamumo is headquartered
LocationHeadquarters
- HQ city
- Suzhou
- HQ country
- China
- HQ region
- Asia
Offices6 records
Markets served
iCamumo business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
Revenue model
- Cell Therapy Product Sales: The company develops and commercializes off-the-shelf (universal) cell therapy drugs derived from iPSCs for oncology (solid tumors, B-cell malignancies, multiple myeloma) and chronic degenerative diseases (Parkinson's, osteoarthritis, ophthalmology). Revenue is expected to come from product sales upon regulatory approval.
- Licensing and Technology Transfer: iCamumo licenses its proprietary TNT reprogramming technology, iCam-iPSC platform, and differentiation technologies to pharmaceutical and biotech partners for drug discovery, disease modeling, and cell therapy development.
Go-to-market motion1 record
Distribution channels2 records
Marketing channels3 records
iCamumo product offering
Product offeringCore offering
iCamumo develops off-the-shelf, universal cell therapy pharmaceuticals derived from induced pluripotent stem cells (iPSCs) for oncology (solid tumors, B-cell malignancies, multiple myeloma) and chronic degenerative diseases (Parkinson's disease, osteoarthritis, ophthalmology). The company leverages its proprietary TNT reprogramming technology and three integrated platforms (iCam-iPSC, iCam-Intelligent Engineering, iCam-Algorithm-Guided Expansion and Differentiation) to produce clinical-grade super-iPSCs and differentiated therapeutic cell products, with planned licensing and product sales revenue streams.
Product overview
iCamumo is a biotech company developing off-the-shelf, effective, and affordable iPSC-based cell therapy drugs. The company operates a platform-plus-products model built on three proprietary technology platforms: the iCam-iPSC Super Stem Cell Platform (using TNT reprogramming for 'super iPSCs'), the iCam-Intelligent Engineering Platform (for gene editing), and the iCam-Algorithm-Guided Expansion and Differentiation Platform (using AI and single-cell multi-omics for cell differentiation). The therapeutic portfolio includes oncology products (ICA01 for solid tumors, ICA01TB for B-cell malignancies, ICA2001 for multiple myeloma, ICA3001 for multi-cancer) and chronic degenerative disease products (ICA03 for osteoarthritis, ICA06 for ophthalmology, ICA07 for Parkinson's disease).
Differentiator
Problem solved
Functional benefit
Products and services
- ICA01
Quantifiable outcome
- TNT reprogramming corrects epigenetic memory and aberrations, producing iPSCs molecularly and functionally closer to ESCs than conventional iPSCs
- +1 more outcomes
Companies that use iCamumo
Customer profileNamed customers2 records
Segments3 records
Ideal customer profiles3 records
iCamumo technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability3 records
Feature4 records
iCamumo partnerships and signals
Strategic signalPartnerships
Three partnerships are on record, tiered major and core.
- University of Western Australia (西澳大学), Monash University (莫纳什大学), University of Adelaide (阿德莱德大学)majorInternational team collaboration for NHMRC-funded project「新型重编程技术开发及应用」(Novel Reprogramming Technology Development and Application). Aims to advance TNT reprogramming technology toward clinical application in cell therapy and regenerative medicine. Prof. Matthew McCormack serves as Senior R&D Director at iCamumo leading this collaboration.
- Cai Lei / Jianyu Huzhu Zhijia (蔡磊 / 渐愈互助之家)coreJoint laboratory establishment for ALS (渐冻症) stem cell disease model and drug screening. iCamumo collaborates with Cai Lei (former JD.com VP and ALS fighter) and his Jianyu Huzhu Zhijia platform (linking thousands of ALS patients) to use iPSC-derived motor neurons and neuromuscular organoids for disease research, drug screening, and evaluation. A mutual strategic partnership combining iCamumo's iPSC technology with the patient's live data platform for ALS research acceleration.
- Zhejiang University School of Medicine Affiliated Second Hospital (浙江大学医学院附属第二医院)coreClinical research collaboration on hiPSC-derived neural cell therapy for Parkinson's disease. Led by Prof. Zhang Baorong (神经内科), with participation of Prof. Yan Feng (功能神经外科) and Prof. Pu Jiali. Combines iCamumo's reprogramming and stem cell differentiation technology with the hospital's neurological clinical expertise. First clinical research collaboration for iCamumo's neural cell therapy pipeline.
Scale indicators6 records
Recent moves6 records
Expansion highlights5 records
iCamumo competitors and assessment
Company assessmentDirect peers
- Fate Therapeutics: Fate Therapeutics is the global leader in off-the-shelf iPSC-derived NK and T cell therapies for oncology, using a comparable platform-plus-products model targeting solid tumors, B-cell malignancies, and multiple myeloma. Closest direct competitor to iCamumo's oncology pipeline (ICA01/ICA01TB/ICA2001/ICA3001).
- Nkarta Therapeutics: Nkarta Therapeutics develops allogeneic off-the-shelf NK cell therapies for hematologic malignancies and solid tumors. Shares iCamumo's positioning around universal cell therapy as a lower-cost alternative to autologous CAR-T.
- Century Therapeutics: Century Therapeutics develops iPSC-derived allogeneic NK and T cell therapies with gene editing for oncology, sharing iCamumo's iPSC-platform-plus-multiplexed-product strategy. Most comparable peer in terms of modality, manufacturing approach, and target indications.
- Shoreline Biosciences: Shoreline Biosciences develops iPSC-derived NK cell immunotherapies for oncology and has multiple Big Pharma partnerships. Comparable to iCamumo's NK-focused solid tumor program with off-the-shelf iPSC platform.
- CellOrigin Biotech: CellOrigin Biotech is a Chinese iPSC-derived cell therapy company developing off-the-shelf CAR-NK and macrophage products for oncology. Closest direct China-based competitor to iCamumo's iPSC NK/T cell pipeline.
Broad incumbents
- Allogene Therapeutics: Allogene is the leading allogeneic CAR-T developer with a broader pipeline of off-the-shelf engineered T cell therapies. Larger and more clinically advanced than iCamumo but operates in the same off-the-shelf cell therapy paradigm for oncology.
- Cellectis: Cellectis is a clinical-stage gene-editing cell therapy company developing allogeneic CAR-T and NK cell platforms using TALEN gene editing. Comparable enabling technology stack to iCamumo's iCam-Intelligent Engineering gene-editing platform.
Emerging players
- Caribou Biosciences: Caribou Biosciences develops allogeneic CAR-NK and CAR-T cell therapies using CRISPR gene editing, with oncology focus. Comparable platform technology approach to iCamumo's gene-edited iPSC-derived immune cells.
- Cytovia Therapeutics: Cytovia develops iPSC-derived NK cells and gene-edited cell therapies for solid tumors and hematologic malignancies. Earlier-stage emerging player with comparable iPSC-NK focus.
Regional players
- JW Therapeutics: JW Therapeutics is a leading China-based cell therapy company commercializing autologous CAR-T products (Carteyva) and expanding into allogeneic formats. Most relevant Chinese peer for understanding local cell therapy commercial dynamics.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
iCamumo social profiles
Digital presenceiCamumo compliance and trust
Trust signalCompliance4 records
iCamumo financial estimates
Financial estimateRevenue estimate
Valuation estimate
iCamumo leadership team
Management profileNumber of profiles
Profiles3 records
iCamumo funding detail
Funding detailFunding overview
Funding rounds5 records
Investors6 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
iCamumo M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about iCamumo
What does iCamumo do?
iCamumo develops off-the-shelf, universal cell therapy pharmaceuticals derived from induced pluripotent stem cells (iPSCs) for oncology (solid tumors, B-cell malignancies, multiple myeloma) and chronic degenerative diseases (Parkinson's disease, osteoarthritis, ophthalmology). The company leverages its proprietary TNT reprogramming technology and three integrated platforms (iCam-iPSC, iCam-Intelligent Engineering, iCam-Algorithm-Guided Expansion and Differentiation) to produce clinical-grade super-iPSCs and differentiated therapeutic cell products, with planned licensing and product sales revenue streams.
Is iCamumo a public or private company?
iCamumo is a private company. It is classified as venture growth investor backed and is currently operating.
When was iCamumo founded?
iCamumo was founded in 2021. It employs 51 to 100 people.
Where is iCamumo based?
iCamumo is headquartered in Suzhou, China, in the Asia region.
How does iCamumo make money?
Two revenue lines are on record. Cell Therapy Product Sales are the primary driver. The others are licensing and Technology Transfer.
Who are iCamumo's main competitors?
Direct peers on record are Fate Therapeutics, Nkarta Therapeutics, Century Therapeutics, Shoreline Biosciences and CellOrigin Biotech. Broad incumbents are Allogene Therapeutics and Cellectis. Emerging players are Caribou Biosciences and Cytovia Therapeutics. JW Therapeutics is listed as a regional player.
Does iCamumo have an API?
No public API is recorded for iCamumo.
What industry is iCamumo in?
iCamumo's product category is Cell Therapy Biopharmaceuticals. Its primary akta.pro industry code is HLAAABAE, Stem Cell Therapies (MSC/iPSC/HSC-derived), with a secondary code of HLAAAGAA, Stem Cell–Based Regenerative Therapies. Its NAICS code is 325414 and its SIC code is 2836.